In this article, we will look at the 10 Best European Growth Stocks to Buy.
European growth stocks are getting another look as investors search for earnings growth outside the usual U.S. mega-cap playbook. Europe is often viewed as a slower-growth market, but that top-down label can miss what is happening underneath the surface. BlackRock says “International equities may present hidden opportunity” and argues that “Europe, Japan and emerging markets show promising prospects in 2026,” helped by improving earnings expectations outside the U.S.
The regional setup is also becoming more interesting. Allianz Global Investors notes that “European equities have made a strong start to 2026,” with major indices “significantly outperforming US markets in euro terms,” while also pointing to “considerable dispersion beneath the surface” and “substantial sector rotation underway.” AllianceBernstein adds the growth-stock angle, saying Europe has “Hidden Champions” and that “Several European sectors are projected to see robust earnings growth.” In summary, Europe’s growth story is about select companies in industries where earnings can grow faster than the region’s broader economy.
Against this backdrop, European growth stocks deserve a closer look, especially those with strong earnings growth, durable competitive positions, and exposure to sectors where demand is holding up better than the macro headlines suggest. With that in mind, let’s take a look at the 10 Best European Growth Stocks to Buy.
Our Methodology
We used the Finviz screener to identify European stocks that are forecasted to grow their EPS by over 20% annually over the next 5 years. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10. argenx SE (NASDAQ:ARGX)
On May 15, 2026, Evercore ISI analyst Gavin Clark-Gartner raised the firm’s price target on argenx SE (NASDAQ:ARGX) to $1,059 from $1,007 while maintaining an Outperform rating on the shares.
Earlier in the week, BofA analyst Tazeen Ahmad raised the firm’s price target on argenx SE (NASDAQ:ARGX) to $1,016 from $1,013 and kept a Buy rating on the shares. BofA said the recent FDA approval expanding the label for Vyvgart and Vyvgart Hytrulo in generalized myasthenia gravis broadens the addressable U.S. patient population by approximately 11,000 patients by extending treatment eligibility across all MG serotypes.
On May 8, 2026, argenx announced that the U.S. FDA approved a label expansion for Vyvgart and Vyvgart Hytrulo for the treatment of adult patients with generalized myasthenia gravis. The supplemental Biologics License Application expands the indication to include all serotypes of adult gMG patients, including anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative patients.
argenx SE (NASDAQ:ARGX) is a commercial-stage biopharmaceutical company focused on developing therapies for autoimmune diseases globally.
9. BeOne Medicines AG (NASDAQ:ONC)
On May 15, 2026, Leerink raised the firm’s price target on BeOne Medicines AG (NASDAQ:ONC) to $367 from $364 while maintaining an Outperform rating on the shares. The firm noted that the FDA granted accelerated approval to sonrotoclax for the treatment of relapsed or refractory mantle cell lymphoma. Leerink added that the approval marks the first regulatory approval for sonrotoclax, with additional studies ongoing across multiple hematologic cancer indications, including combinations with zanubrutinib and anti-CD20 antibodies.
On May 13, 2026, BeOne Medicines announced that the U.S. FDA granted accelerated approval to Beqalzi, its next-generation BCL2 inhibitor, for adult patients with relapsed or refractory mantle cell lymphoma following at least two prior lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor. The company said Beqalzi was designed to improve BCL2 inhibition through greater potency, selectivity, and a pharmacologic profile that could potentially improve efficacy, tolerability, and convenience compared to existing therapies in the class. Continued approval for the indication remains contingent on confirmation of clinical benefit in the ongoing CELESTIAL-RRMCL confirmatory trial. The FDA also granted Breakthrough Therapy, Fast Track, and Orphan Drug designations for sonrotoclax in this indication.
Earlier in May, BeOne Medicines AG (NASDAQ:ONC) reported Q1 adjusted EPS of $3.24, compared to $1.22 in the prior-year quarter. Revenue totaled $1.51B, ahead of the consensus estimate of $1.44B. Co-Founder, Chairman, and CEO John Oyler said the quarter reflected continued growth driven by commercial execution and expanding leadership in hematology, alongside the company’s growing solid tumor pipeline. Oyler also highlighted the continued momentum of BRUKINSA, which management described as a foundational BTK inhibitor with strong long-term efficacy and safety data in chronic lymphocytic leukemia. The company additionally pointed to the combination of sonrotoclax and BRUKINSA as a potential future standard-of-care treatment in first-line CLL.
BeOne Medicines AG (NASDAQ:ONC) develops oncology therapies focused on hematologic cancers and solid tumors across global markets.
